A non-prescription intranasal application of APTT3X™ formulation will DECREASE the risk of contracting COVID-19 by 150% . APTT3X™ is a self-administered process of swabbing the lower passages of the nose, represents a scalable preventative solution that could slow the spread of COVID-19 on a global scale” — Dr. Ernesto Cesar Pinto Leal Junior, ELJ ConsultancyROCKWALL, TEXAS, UNITED STATES, April 21, 2021 /EINPresswire.com/ -- The efficacy of the APTT3X™ formulation has been validated in a just-completed clinical trial conducted in Brazil under “Black Flag” conditions. The da...